A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Atorvastatin/fimasartan (Primary) ; Atorvastatin; Fimasartan
- Indications Dyslipidaemias; Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FIESTA
- Sponsors Boryung Pharmaceutical
- 18 Jan 2018 Planned end date changed from 30 Nov 2018 to 28 Feb 2019.
- 18 Jan 2018 Planned primary completion date changed from 31 Oct 2018 to 30 Nov 2018.
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.